Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Approved For Marketing No phase listed Expanded access

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT00130897

Public ClinicalTrials.gov record NCT00130897. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.

Study identification

NCT ID
NCT00130897
Recruitment status
Approved For Marketing
Study type
Expanded access
Phase
Not listed
Lead sponsor
Pfizer
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2005 (Type not available)
Primary completion
Nov 2011 (Actual)
Completion
Nov 2011 (Actual)
Last update posted
Mar 9, 2012

2005 – 2011

United States locations

U.S. sites
53
U.S. states
28
U.S. cities
38
Facility City State ZIP Site status
Pfizer Investigational Site Scottsdale Arizona 85260 —
Pfizer Investigational Site San Francisco California 94115-2378 —
Pfizer Investigational Site San Francisco California 94115 —
Pfizer Investigational Site Aurora Colorado 80040-0510 —
Pfizer Investigational Site Norwalk Connecticut 06856 —
Pfizer Investigational Site Miami Florida 33176 —
Pfizer Investigational Site Ocala Florida 34474 —
Pfizer Investigational Site Tampa Florida 33612 —
Pfizer Investigational Site Atlanta Georgia 30309 —
Pfizer Investigational Site Maywood Illinois 60153 —
Pfizer Investigational Site Indianapolis Indiana 46260-2082 —
Pfizer Investigational Site Council Bluffs Iowa 51503 —
Pfizer Investigational Site Covington Louisiana 70433 —
Pfizer Investigational Site Gretna Louisiana 70056 —
Pfizer Investigational Site Marrero Louisiana 70072 —
Pfizer Investigational Site Metairie Louisiana 70002 —
Pfizer Investigational Site Metairie Louisiana 70006 —
Pfizer Investigational Site New Orleans Louisiana 70115 —
Pfizer Investigational Site Baltimore Maryland 21287 —
Pfizer Investigational Site Boston Massachusetts 02114 —
Pfizer Investigational Site Boston Massachusetts 02115 —
Pfizer Investigational Site Boston Massachusetts 02215 —
Pfizer Investigational Site Detroit Michigan 48201 —
Pfizer Investigational Site Minneapolis Minnesota 55455 —
Pfizer Investigational Site Southaven Mississippi 38671 —
Pfizer Investigational Site Tupelo Mississippi 38801 —
Pfizer Investigational Site Columbia Missouri 65201 —
Pfizer Investigational Site Columbia Missouri 65203 —
Pfizer Investigational Site Omaha Nebraska 68198-7680 —
Pfizer Investigational Site New York New York 10021 —
Pfizer Investigational Site New York New York 10022 —
Pfizer Investigational Site The Bronx New York 10466 —
Pfizer Investigational Site Durham North Carolina 27710 —
Pfizer Investigational Site Cleveland Ohio 44195 —
Pfizer Investigational Site Norman Oklahoma 73071 —
Pfizer Investigational Site Oklahoma City Oklahoma 73102 —
Pfizer Investigational Site Oklahoma City Oklahoma 73109 —
Pfizer Investigational Site Oklahoma City Oklahoma 73112 —
Pfizer Investigational Site Oklahoma City Oklahoma 73120 —
Pfizer Investigational Site Tulsa Oklahoma 74104 —
Pfizer Investigational Site Tulsa Oklahoma 74136-1902 —
Pfizer Investigational Site Portland Oregon 97210 —
Pfizer Investigational Site Portland Oregon 97227 —
Pfizer Investigational Site Hershey Pennsylvania 17033-0850 —
Pfizer Investigational Site Memphis Tennessee 38104 —
Pfizer Investigational Site Memphis Tennessee 38120 —
Pfizer Investigational Site Dallas Texas 75246 —
Pfizer Investigational Site Salt Lake City Utah 84112 —
Pfizer Investigational Site Seattle Washington 98104 —
Pfizer Investigational Site Seattle Washington 98109 —
Pfizer Investigational Site Seattle Washington 98122 —
Pfizer Investigational Site Seattle Washington 98124 —
Pfizer Investigational Site Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 218 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00130897, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2012 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00130897 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →